Piramal Pharma Limited · NSE:PPLPHARMA
Piramal Pharma — Q1 FY2024 Earnings Presentation
31 slides from Piramal Pharma's earnings presentation, Aug 3, 2023
Slide 1: Exchange cover letter for press release and investor presentation
3rd August, 2023 BSE Limited National Stock Exchange of India Limited P.J. Towers, Dalal Street, Fort, Exchange Plaza, Bandra-Kurla Complex, Mumbai- 400 001 Bandra (East), Mumbai – 400 051 BSE scrip code: 543635 NSE symbol: PPLPHARMA Sub: Press Release and Investor Presentation – Unaudited Financial
Slide 2: Piramal Pharma Limited Announces Consolidated Results for Q1FY24
PRESS RELEASE Piramal Pharma Limited Announces Consolidated Results for Q1FY24 Mumbai, India | August 3, 2023: Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), today announced its consolidated results for the first quarter (Q1) ended 30th June 2023. Consolidated Financial Highlights (In INR Cr
Slide 3: Key Business Highlights for Q1FY24
Key Business Highlights for Q1FY24 Contract Development and Manufacturing Organization (CDMO): - Witnessed continued order inflow momentum and strong execution in Q1FY24. Continue to see good demand for our differentiated offering in the niche areas of high potent API, peptide, anti-body drug conjug
Slide 4: Consolidated Profit and Loss Statement
Consolidated Profit and Loss Statement (In INR Crores) Reported Financials Particulars Q1FY24 Q1FY23 YoY Change Q4FY22 QoQ Change Revenue from Operations 1,749 1,482 18% 2,164 -19% Other Income 38 72 -47% 25 56% Total Income 1,787 1,554 15% 2,188 -18% Material Cost 627 574 9% 840 -25% Employee Expen
Slide 5: Q1FY24 Earnings Conference Call
Q1FY24 Earnings Conference Call Piramal Pharma Limited will be hosting a conference call for investors / analysts on 4th August 2023 at 10:00 AM (IST) to discuss its Q1FY24 Results. The dial-in details for the call are as under: Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8
Slide 6: Piramal Pharma Limited Q1FY24 Results
Piramal Pharma Limited – Q4 and FY2023 Results Presentation Piramal Pharma Limited Q1FY24 Results August 2023
Slide 7: Disclaimer
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 2 Disclaimer This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommen
Slide 8: Key Performance Highlights of Q1FY24
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 3 Key Performance Highlights of Q1FY24 Key Highlights Revenue and EBITDA performance in Q1FY24 Revenue EBITDA Margin In Q1FY24, Revenue grew by 18% YoY and EBITDA margin was 10% (In INR Crore) 6%* 10% Business Segment Revenues (INR Cr.) Yo
Slide 9: Details on the Rights Issue
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 4 Details on the Rights Issue Progress on the Rights Issue not exceeding INR 1,050 Crore Company has filed the Letter of Offer (LOF) with SEBI Issue Details Rights Issue Price – INR 81 Total number of Equity Shares and Rights Issue s
Slide 10: Business-wise Performance
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 5 Business‐wise Performance
Slide 11: Contract Development and Manufacturing Organization Business
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 6 Contract Development and Manufacturing Organization Business Performance Highlights Revenue performance in Q1FY24 Continued momentum in order inflows: (In INR Crore) • Company witnessed significant pick‐up in order bookings in Q4FY23 whi
Slide 12: Pick-up in Order Inflows
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 7 Pick‐up in Order Inflows Witnessing pick‐up in order inflows for differentiated offerings and innovation related work FY23 Revenue by Services Pre-clinical Deepening the development pipeline by: 20% • Increasing the proposal velocity – S
Slide 13: Focused CapEx at Sites with Differentiated Offerings
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 8 Focused CapEx at Sites with Differentiated Offerings Recently opened capacity expansions seeing encouraging response Riverview (HP API) Aurora (HP API) Potent sterile Peptide Customer‐led injectables capacity expansion to drive share of CD
Slide 14: Leverage Integrated Service Offerings
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 9 Leverage Integrated Service Offerings Benefits of the Integrated Services driving customer demand Integrated project is defined as project involving more than one site The Company has built a platform for Integrated Service offering th
Slide 15: Continue to Maintain Best-in-Class Quality Track Record
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 10 Continue to Maintain Best‐in‐Class Quality Track Record 5 8 Zero Successfully cleared multiple customer Successful US FDA Successful regulatory inspections since inspections in OAIs1,2 audits November 2022 Q1FY24 Riverview, USA ‐ November
Slide 16: Complex Hospital Generics Business
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 11 Complex Hospital Generics Business Performance Highlights Revenue growth in Q1FY24 (In INR Crore) Strengthened the CHG Leadership Team ‐ Appointed Jeffrey Hampton as President & Chief Operating Officer for CHG business • Previously, he
Slide 17: Expansion of Inhalation Anaesthesia Capacities
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 12 Expansion of Inhalation Anaesthesia Capacities Expanding inhalation anaesthesia capacities to meet high global demand Inhalation anesthesia facility Inhalation anesthesia facility Specialty Fluorochemicals facility (Bethlehem, USA) (Digwa
Slide 18: Building Pipeline of New Products
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 13 Building Pipeline of New Products Existing product portfolio characterized by high barriers to entry and low competition Inhalation Anaesthesia Intrathecal Therapy Injectable Anesthesia Other Products and pain management (Injectables) Bui
Slide 19: Leverage Presence in 100+ Countries
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 14 Leverage Presence in 100+ Countries Leveraging our worldwide marketing and sales network to increase our product market share in global markets Established channel relationships and robust commercial infrastructure Direct sales force
Slide 20: India Consumer Healthcare Business
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 15 India Consumer Healthcare Business Performance Highlights Revenue growth in Q1FY24 New Product launches ‐ 11 new products and 3 new SKUs launched in Q1FY24 (In INR Crore) 239 211 Power Brands comprising of Lacto Calamine, Littles, Pol
Slide 21: Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 16 Focus on Power Brands with Continuous Investments in Brand Promotion and Marketing Investments in brand promotion and marketing Strong growth in power brands (In INR Crore) 38% CAGR 367 267 194 Kareena Kapoor Shriya Pilgaonkar Amyra Dastu
Slide 22: Leverage Multi-channel Distribution Network and New Product Launches
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 17 Leverage Multi‐channel Distribution Network and New Product Launches Well established commercial infrastructure with multi‐channel distribution strategy Wide coverage across general Strengthening presence in Expanding presence on Direct‐t
Slide 23: Diversified Portfolio of Attractive Brands, Including Power Brands
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 18 Diversified Portfolio of Attractive Brands, Including Power Brands Kids wellness Analgesics Skin care VMS Women’s health Digestives Health & Hygiene Lacto Calamine i‐pill, i‐know Littles Supradyn Contraceptive Pill, Saridon Oil Control Lo
Slide 24: Joint Venture with Allergan
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 19 Joint Venture with Allergan Joint Venture Arrangement *now AbbVie Ownership Ownership 49% 51% One of the market 400+ Strong presence glaucoma, dry eye, 40+ Brands Refresh Tears, leaders in Indian employees including Ophthalmology segment
Slide 25: Sustainability Initiatives
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 20 Sustainability Initiatives
Slide 26: Integrating Sustainability in Operations
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 21 Integrating Sustainability in Operations Global Human Rights Adopted and published Company’s Global Human Right Statement in accordance to the United Nations Policy Universal Declaration of Human Rights (UDHR) and Guiding Principles on
Slide 27: Integrating Sustainability in Operations
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 22 Integrating Sustainability in Operations Committed to SBTi (Science Based Target initiatives) – Made a formal commitment to the SBTi. By doing so, have pledged to set science‐based targets to reduce greenhouse gas emissions (GHG) in lin
Slide 28: Financials
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 23 Financials
Slide 29: Consolidated Financials Highlights
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 24 Consolidated Financials Highlights (In INR Crores or as stated) Reported Financials Particulars Q1FY24 Q1FY23 YoY Change Q4FY23 QoQ Change Revenue from Operations* 1,749 1,482 18% 2,164 ‐19% CDMO 898 770 17% 1,285 ‐30% CHG 617 508 22% 702
Slide 30: Dial-in details for Q1FY24 Earnings Conference Call
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 25 Dial‐in details for Q1FY24 Earnings Conference Call Event Location & Time Telephone Number +91 22 6280 1461 / +91 22 7115 8320 (Primary Number) India – 10:00 AM IST 1 800 120 1221 (Toll free number) USA – 12:30 AM Toll free number Confere
Slide 31: For Investor Queries
Piramal Pharma Limited – Q1 FY24 Results Presentation Page 26 For Investor Queries: Gagan Borana General Manager – Investor Relations & Sustainability Email : gagan.borana@piramal.com Phone : +91 22 3802 3090